Presenter: Jamie Edgin, Ph.D
Dr. Jamie Edgin is a tenured Associate Professor and Co-Director of the Cognition and Neural Systems Program in the Department of Psychology at the University of Arizona. Her research centers on understanding the neurological basis for sleep, memory, and language impairment in developmental disorders, particularly Down syndrome (DS) and autism. She has received several awards for her work in intellectual and developmental disabilities, including the 2018 University of Arizona Koffler Prize, the Charles Epstein award from the National Down Syndrome Society, and the Inaugural David Cox “Rising Star” award from the LuMind IDSC Foundation. She is an expert in Developmental Cognitive Neuroscience, with several published works on sleep, memory, and neuroimaging in typical children, DS, and other at-risk groups. She has >40 published papers employing sleep and neurocognitive assessment, EEG/ERP, fMRI, and eyetracking methodologies in these populations. She serves on several editorial boards for leading national and international journals focused on developmental disability and regularly participates in grant review for various granting agencies. Dr. Edgin’s team has just finished data collection on the first longitudinal study to examine sleep disturbance and development in infants and toddlers with DS from 6-24 months of age. Further, she currently leads a NIH-funded multisite study to design and validate a new neuropsychological assessment tool for use in intellectual disabilities, the “Arizona Memory Assessment for Preschoolers and Special Populations.” She was instrumental in the design and validation of one important battery of cognitive tests validated specifically for use in DS: The Arizona Cognitive Test Battery.
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.
CTAD 2019 will highlight the latest on trying to get these trials off the ground.
Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.
Prof. Judith Jaeger
PhD, MPA, President and Principal Scientist at CognitionMetrics, LLC
Dr. Jaeger is an internationally recognized clinical neuropsychologist and pharmaceutical executive. She was previously the Vice President for Clinical Trials at Cogstate, Inc, and Director Clinical Development at AstraZeneca Pharmaceuticals, Inc.
– Clinical and pharmaceutical development expert on cognitive, psychiatric and neurological disorders
– Sought after key opinion leader and scientific consultant to most (14 of top 25) major pharma companies and several CRO’s and biotechs working in neuroscience.
The night will be a cocktail-formal affair, with a live blues band, great food, original art, an open bar, and a lot of fun.
Tickets are $75 each or $125 for two tickets. You can buy tickets (or donate in lieu of buying tickets) by clicking on the link below.
LuMind IDSC Foundation is proud to be a Bronze sponsor of the 2020 DSAIA Conference. We are looking forward to reuniting with our Down syndrome affiliates on February 27th in sunny Orlando, Florida to continue collaborating in our shared goals of improving health and independence in individuals with Down syndrome. Swing by the LuMind IDSC Foundation @ Booth # 5 to learn more about the exciting research, LIFE-DSR and the new LuMind IDSC initiatives for the Down syndrome community.
Join Our Workshops
To register or find out more information about the conference go to the DSAIA website. Our thanks to DSAIA and the conference committee for their exceptional work organizing this important meeting.
World Down Syndrome Day (WDSD) is a global awareness day selected to signify the uniqueness of the three copies of the 21st chromosome. Join us in celebrating individuals with Down syndrome and their accomplishments. Let’s show the world how they soar!
Please visit www.lumindidsc.org/soar for more information.
LuMind IDSC’s Recorded Presentations
At NDSS Virtual Summit
If you were unable to join our live presentations and LuMind IDSC’s Lunch and Learn you can still register and Save 21% with the LuMindIDSC2020 code.
LuMind IDSC Scheduled Sessions:
Join our Chief Scientific Officer, Jim Hendrix to find out what LuMind IDSC is doing to prevent Alzheimer’s in Down Syndrome.
Advances in Down Syndrome Research with Hampus Hillerstrom, LuMind IDSC’s President & CEO
Down Syndrome & Sleep and Sleep Apnea with CSO, James Hendrix.
Virtual Lunch and Learn with NDSS and LuMind IDSC!
Join us for the first NDSS Adult Summit Virtual Lunch and Learn, hosted and moderated by LuMind IDSC, where you get to decide what you want to hear from a panel of speakers with over four decades of experience as caregivers, healthcare providers, and Alzheimer’s research for adults with Down syndrome.
Dr. James Hendrix, the Chief Scientific Officer of LuMind IDSC will present your questions to the panelists who will answer as many as they can that day.
Panelist speakers: Dr. Brian Chicoine Co-founder and Medical Director of the Advocate Medical Group Adult Down Syndrome Center, Dr. Anna Burke, Geriatric Psychiatrist and the Director of Neuropsychiatry at Barrow Neurological Institute, Dr. Matt Janicki, Co-chair of the National Task Group on Intellectual Disabilities and Dementia Practices (NTG) and Phyllis Ferrell, Head External Engagement, Alzheimers, and Neurodegeneration at Eli Lilly and Company. Founder Women Against Alzheimer’s
Stop by our Virtual booth at https://www.ndss.org/virtual-exhibit-booth/lumind-idsc/
LuMind IDSC and NDSS Focus Groups
LuMind IDSC and NDSS are seeking parents or caregivers of individuals with Down syndrome to participate in a focus group aimed to gather information regarding experiences, motivations and thoughts pertaining to aging with Down syndrome to increase our understanding and shape future initiatives and services.
Participants will be asked to provide feedback, thoughts and reactions on individual motivation, communication, social inclusion, employment, health and health habits related to aging with Down syndrome.
The focus groups will take place through a Virtual Zoom Call on the following dates and times. To sign up, please click here.
Focus Group June 4th @ 3:30-4:30 pm EST
The 2020 NDSS Virtual Adult Summit is open to all individuals who play any role in the life of individuals who have Down syndrome or are within the IDD community with a specific focus on caregivers, family members, professionals, and individuals with Down syndrome. Our Virtual Summit will take place on various dates and times throughout May.
This Virtual Summit will cover important and critical topics for all adults with Down syndrome and IDD. Speakers and topics will align with NDSS’ comprehensive programs and pillars – including healthcare, research, inclusive education, community integration, caregiving, economic self-sufficiency, aging-related health issues, and employment.
Paving the Way to a Bright Future Through Innovative Research
MDSC 36th Annual Virtual Conference
Register today so you will be one of the first people to access the virtual conference when it goes live in mid-June!
LuMind IDSC’s recorded presentations
Accelerating Research in Down syndrome
Hampus Hillerstrom, President & CEO, LuMind IDSC; Stefan Pinter, PhD, Assistant Professor, University of Connecticut Health
Research advances in Alzheimer’s disease, sleep, speech, cognition and auto-immune conditions show potential to improve the health of people with Down syndrome (DS). The Down Syndrome – Clinical Trial Network and the clinical trial, the LIFE-DSR Study, have been launched to accelerate DS research. Results from recent family surveys on sleep apnea and independence and the launch of the new online resource for families, the Down Syndrome Clinic 2 You (DSC2U), will be included. Dr. Pinter will cover recent work evaluating the potential to silence chromosome 21 in cells. New approaches to remaining challenges toward this goal will be addressed.
Alzheimer’s Disease in Down syndrome: What We Know, What Gives Us Hope for the Future
James Hendrix, PhD, Chief Scientific Officer, LuMind IDSC
Individuals with Down syndrome face a higher risk for Alzheimer’s disease later in life, but what can we learn from current research and what gives us hope for the future? This session will provide an overview of recent progress in Alzheimer’s disease research and how this could help people with Down syndrome in the future.
Register today so you will be one of the first people to access the virtual conference when it goes live in June. You’ll receive a link and personal custom password via email for the site. The registration fee is only $29.99 per household and will include access to all the presentations that you can view at your convenience through the end of the 2020 calendar year.